Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.

Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia / I. Ardoino, F. Ambrogi, S. Iacobelli, P. Boracchi, G. Manikis, M.G. Kounelakis, M. Zervakis, P.J.G. Lisboa, P. Fazi, M. Vignetti, E. Biganzoli, A. Starita. - In: INTERNATIONAL JOURNAL OF BIOMEDICAL ENGINEERING AND TECHNOLOGY. - ISSN 1752-6418. - 3:3/4(2010), pp. 329-348. [10.1504/IJBET.2010.032699]

Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia

I. Ardoino;F. Ambrogi;P. Boracchi;E. Biganzoli;
2010

Abstract

Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.
Acute myeloid leukaemia; AML; Competing risks; CR; Multinomial logistic regression; Support vector machines; Survival analysis
Settore MED/01 - Statistica Medica
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/147378
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact